Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study

The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. We prospectively examined the association between saxagliptin use and acute myocardial infarction (AMI). We identified patients aged ≥18 years, start...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2018-01, Vol.41 (1), p.39-48
Hauptverfasser:	Toh, Sengwee, Reichman, Marsha E, Graham, David J, Hampp, Christian, Zhang, Rongmei, Butler, Melissa G, Iyer, Aarthi, Rucker, Malcolm, Pimentel, Madelyn, Hamilton, Jack, Lendle, Samuel, Fireman, Bruce H
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adamantane - analogs & derivatives Adamantane - therapeutic use Dipeptides - therapeutic use Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Female Follow-Up Studies Health risks Heart attacks Humans Hypoglycemic Agents - therapeutic use Identification methods Incidence Insulin Insulin, Long-Acting - therapeutic use Male Middle Aged Myocardial infarction Myocardial Infarction - drug therapy Myocardial Infarction - epidemiology Peptidase Pioglitazone Population studies Population-based studies Prescription drugs Product Surveillance, Postmarketing Propensity Score Proportional Hazards Models Prospective Studies Research design Safety Sequential analysis Sitagliptin Phosphate - therapeutic use Sulfonylurea Compounds - therapeutic use Surveillance Thiazolidinediones - therapeutic use United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!